Skip to main content Back to Top


Methenamine Hippurate Tablets

Products Affected - Description

    • Hiprex oral tablet, Validus Pharmaceuticals, 1 gram, bottle, 100 NDC 30698-0277-01
    • Methenamine hippurate oral tablet, Alvogen, 1 gram, bottle, 100 NDC 47781-0577-01
    • Methenamine hippurate oral tablet, Micro Labs, 1 gram, bottle, 100 NDC 42571-0332-01

Reason for the Shortage

    • Alvogen did not provide a reason for the shortage.
    • Aurobindo refuses to provide us with availability information.
    • Amneal discontinued methenamine hippurate in 2018.
    • Leading Pharma discontinued methenamine hippurate in 2017 due to a raw materials shortage.
    • Micro Labs has methenamine hippurate on shortage due to increased demand.
    • Validus Pharmaceuticals did not provide a reason for the shortage.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Alvogen has temporarily discontinued methenamine hippurate tablets.
    • Micro Labs has methenamine hippurate tablets on allocation.
    • Validus has Hiprex on back order and the company cannot estimate an estimated release date.


Updated May 1, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 12, 2020 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.